South San Francisco, CA ; 03/19/2020
Amount Funded: $45 Million
Type: Series B
Lead Investor: The Column Group, Nextech Invest
Participating Investor(s): ShangPharma, LifeForce Capital, Berkeley Catalyst Fund
Company Description: Circle is developing a new paradigm for macrocycle drug discovery based on rational design and synthetic chemistry. Circle’s technology facilitates the design and synthesis of intrinsically cell-permeable macrocycles that can address both intra- and extra-cellular therapeutic targets, and can be delivered by oral administration. Circle’s macrocycle development platform is applicable across a wide range of serious diseases; the company is initially focusing its development efforts on intracellular protein-protein interactions that are key drivers in cancer. Its lead program targets cyclins A and E, which are part of the regulatory machinery that controls the progression of cells through the cell growth and division cycle. Inhibiting cyclins A and E has been shown to be synthetically lethal in cancers that carry mutations causing dysregulation of the Rb pathway.
What funding will be used for: “Proceeds from the investment will be used to advance Circle’s work to develop inhibitors of Cyclin A and Cyclin E, and to expand the company’s pipeline.”
“We are delighted to have these premier life science investors supporting our Series B financing. With this strong backing, we will expand our team, drive our cyclin targeted programs towards the clinic, and apply our macrocycle platform to additional intractable targets.”
-David J. Earp, J.D., Ph.D, Circle’s President and CEO
- Peter Svennilson, founder, managing partner of The Column Group, and Thilo Schroeder, Ph. D. partner, Nextech Invest, join Circle Pharma, board of directors.
Data provided by respective company (unless otherwise noted) and researched by StartupsOne for accuracy.